JP2025506383A5 - - Google Patents
Info
- Publication number
- JP2025506383A5 JP2025506383A5 JP2024545929A JP2024545929A JP2025506383A5 JP 2025506383 A5 JP2025506383 A5 JP 2025506383A5 JP 2024545929 A JP2024545929 A JP 2024545929A JP 2024545929 A JP2024545929 A JP 2024545929A JP 2025506383 A5 JP2025506383 A5 JP 2025506383A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dose
- dose form
- raav particles
- eye
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305838P | 2022-02-02 | 2022-02-02 | |
| US63/305,838 | 2022-02-02 | ||
| US202263336191P | 2022-04-28 | 2022-04-28 | |
| US63/336,191 | 2022-04-28 | ||
| US202263336789P | 2022-04-29 | 2022-04-29 | |
| US63/336,789 | 2022-04-29 | ||
| US202263339795P | 2022-05-09 | 2022-05-09 | |
| US63/339,795 | 2022-05-09 | ||
| US202263435103P | 2022-12-23 | 2022-12-23 | |
| US63/435,103 | 2022-12-23 | ||
| PCT/US2023/061769 WO2023150566A1 (en) | 2022-02-02 | 2023-02-01 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506383A JP2025506383A (ja) | 2025-03-11 |
| JP2025506383A5 true JP2025506383A5 (https=) | 2026-02-25 |
Family
ID=85569710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024545929A Pending JP2025506383A (ja) | 2022-02-02 | 2023-02-01 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250137011A1 (https=) |
| EP (1) | EP4473003A1 (https=) |
| JP (1) | JP2025506383A (https=) |
| KR (1) | KR20240145489A (https=) |
| AU (1) | AU2023216244A1 (https=) |
| CA (1) | CA3243256A1 (https=) |
| IL (1) | IL314455A (https=) |
| MX (1) | MX2024009478A (https=) |
| WO (1) | WO2023150566A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025010334A2 (en) * | 2023-07-05 | 2025-01-09 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| WO2026019885A1 (en) * | 2024-07-16 | 2026-01-22 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
-
2023
- 2023-02-01 US US18/834,864 patent/US20250137011A1/en active Pending
- 2023-02-01 EP EP23710583.8A patent/EP4473003A1/en active Pending
- 2023-02-01 CA CA3243256A patent/CA3243256A1/en active Pending
- 2023-02-01 IL IL314455A patent/IL314455A/en unknown
- 2023-02-01 WO PCT/US2023/061769 patent/WO2023150566A1/en not_active Ceased
- 2023-02-01 JP JP2024545929A patent/JP2025506383A/ja active Pending
- 2023-02-01 KR KR1020247028962A patent/KR20240145489A/ko active Pending
- 2023-02-01 AU AU2023216244A patent/AU2023216244A1/en active Pending
-
2024
- 2024-07-31 MX MX2024009478A patent/MX2024009478A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547541A5 (https=) | ||
| JP2025506383A5 (https=) | ||
| JP2024515459A5 (https=) | ||
| FI4027983T3 (fi) | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla | |
| EP3471780B1 (en) | Treatment of amd using aav2 variant with aflibercept | |
| JP2021503914A5 (https=) | ||
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2020526514A5 (https=) | ||
| JP2020537637A5 (https=) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2022522776A5 (https=) | ||
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| RU2014150340A (ru) | Лечение amd с применением экспессируемого aav sflt-1 | |
| JP2025506681A5 (https=) | ||
| JP2022545967A5 (https=) | ||
| JP2021511030A5 (https=) | ||
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2022500353A (ja) | Ｉｇｆ−１−暗号化ｄｎａ作製物及びｈｇｆ−暗号化ｄｎａ作製物を用いた神経病症治療 | |
| WO2021050094A1 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| JP2025509568A5 (https=) | ||
| CA3178591A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| JP2020537675A (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 | |
| JP2022523050A5 (https=) | ||
| JP2024148177A (ja) | アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法 | |
| JP7766054B2 (ja) | 眼病態の処置のためのｄｎａ構造 |